What's Happening?
Viridian Therapeutics, Inc. has entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited. This agreement, effective from May 24, 2026, involves WuXi Biologics manufacturing and supplying Viridian's anticipated
long-term requirements of the veligrotug drug substance and product for commercial use, pending approval. WuXi Biologics will serve as a non-exclusive supplier, allowing Viridian to source the product from other manufacturers if needed. The agreement includes a provision for Viridian to provide monthly rolling forecasts of volume requirements, with a portion being a binding commitment. Pricing is volume-based, with fees fixed until the end of 2026, after which they may be adjusted annually. The initial term of the agreement is five years, with automatic renewals unless terminated by either party with 24 months' notice. Termination can also occur due to legal changes affecting WuXi's ability to perform, material breaches, or insolvency.
Why It's Important?
This partnership is significant for Viridian Therapeutics as it secures a reliable manufacturing source for its veligrotug drug, which is crucial for its commercial strategy. The agreement with WuXi Biologics, a prominent player in the biologics manufacturing sector, ensures that Viridian can meet its production needs efficiently. This could enhance Viridian's market position and operational stability, potentially leading to increased investor confidence and market share. For WuXi Biologics, this agreement expands its client base and reinforces its role as a key supplier in the biopharmaceutical industry. The collaboration highlights the growing trend of biopharmaceutical companies outsourcing manufacturing to specialized firms, which can lead to cost efficiencies and focus on core competencies.
What's Next?
The next steps involve Viridian providing regular forecasts to WuXi Biologics and preparing for potential commercial production, contingent on regulatory approvals. Both companies will need to ensure compliance with the agreement's terms, including quality and regulatory standards. The automatic renewal clause suggests a long-term collaboration, provided both parties are satisfied with the partnership's outcomes. Any changes in laws affecting WuXi's operations could prompt renegotiations or adjustments to the agreement. Stakeholders will be watching for any updates on the drug's approval status, which will significantly impact the agreement's execution.
